TBPH

TD-1473 (GUT-SELECTIVE JAK INHIBITOR)

Ulcerative colitis

Stage (next event)

Expected Date

Phase 2b/3 (Top-line Data)

Q3 2021

Catalyst Info & Data Links

TITLE: TD-1473 (GUT-SELECTIVE JAK INHIBITOR) for Ulcerative colitis - Phase 2b/3 Data

  • ClinicalTrial.gov (NCT03758443): Efficacy & Safety of TD-1473 in Ulcerative Colitis (RHEA)


WHAT IS THE CATALYST EVENT?

  • Phase 2b Top-line Data


WHEN WILL THE EVENT (OR DID THE EVENT) OCCUR?


PRIOR DATA/EVENTS

PRESS RELEASE


Mechanism of Action

MECHANISM OF ACTION

  • TD-1473 is an internally-discovered JAK inhibitor that has demonstrated a high affinity for each of the JAK family of enzymes. Importantly, TD-1473 is a gut-selective treatment specifically designed to distribute adequately and predominantly to the tissues of the intestinal tract, treating inflammation in those tissues while minimizing its systemic exposure.

MARKET

  • Ulcerative colitis and Crohn's disease, which affect roughly 900,000 and 700,000 patients in the United States, respectively.

Updated by HC

Prior Data (click to view full image)

Chart

Trial Design / Revenue (click to view full image)

Chart

Recent Posts

See what the community is saying - click to see full post

TBPH To Report On nOH Results For TD-9855 This Month - Medium Risk And Reward

*Disclaimer: Information provided on ampbiotechresearch.com and in any of our reports, products and services are for information only and are not investment advice. Please consult with an investment adviser and do your own diligence before making any investment decisions or taking any action.  By accessing this site, you agree to our Terms of Use and Privacy Policy that can be accessed here. Amp Core™ is a trademark of Amp Biotech Research, LLC

©2020 BY Amp Biotech Research

  • Twitter Social Icon
  • LinkedIn Social Icon